A National, Prospective, Non-interventional Study of NINLARO in Real World Clinical Practice
Latest Information Update: 10 Mar 2026
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Takeda
Most Recent Events
- 04 Mar 2026 Actual Primary Completion Date is 13 Feb 2026.
- 04 Mar 2026 Status changed from active, no longer recruiting to completed.
- 10 Apr 2025 Planned End Date changed from 30 Sep 2025 to 30 Mar 2026.